Tango Therapeutics Financial Ratios
NASDAQ: TNGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
23.81+1.24 (+5.49%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tango Therapeutics ratio analysis
Tango Therapeutics earned a net margin of -162.9% in FY 2025, up from -309.7% a year earlier. Return on equity reached -29.3%, meaning Tango Therapeutics generated -0.29 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Tango Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Price / sales | 16.63 | 8.18 | 25.63 | 25.61 | 18.34 | 47.71 |
| Price / book | 3.00 | 1.72 | 3.70 | 2.55 | 1.97 | 9.46 |
| Operating margin | -178.4% | -346.1% | -312.6% | -446.8% | -157.1% | -681.8% |
| Net margin | -162.9% | -309.7% | -278.5% | -435.1% | -157.2% | -678.8% |
| Free cash flow margin | -224.3% | -314.4% | -327.2% | -469.7% | -165.7% | 900.8% |
| Return on equity (ROE) | -29.3% | -65.3% | -40.2% | -43.4% | -16.9% | -134.6% |
| Return on assets (ROA) | -25.5% | -41.2% | -25.3% | -24.8% | -11.6% | -25.1% |
| Current ratio | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 | 4.73 |
| Revenue growth | 48.3% | 15.2% | 46.9% | -32.9% | 383.8% | — |